贝达药业(300558) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥985,929,981.64, representing a 16.83% increase year-over-year[6] - Net profit attributable to shareholders decreased by 7.93% to ¥177,035,133.47 for the quarter, and by 23.86% to ¥316,932,355.32 for the year-to-date[6] - The net profit excluding non-recurring items was ¥146,603,519.66, a slight increase of 1.08% compared to the same period last year[6] - Operating income for the year-to-date was ¥2,717,342,723.91, up 15.90% due to increased pharmaceutical sales and the gradual release of new products[10] - Total operating revenue increased to ¥2,717,342,723.91, up from ¥2,344,643,009.24, representing a growth of approximately 15.9% year-over-year[26] - Net profit for the period was ¥303,006,092.01, down from ¥405,153,844.02, indicating a decline of approximately 25.3% year-over-year[27] - Earnings per share decreased to ¥0.76 from ¥0.99, representing a decline of about 23.2%[27] Assets and Liabilities - Total assets at the end of the quarter amounted to ¥9,699,462,636.70, reflecting a 3.83% increase from the end of the previous year[6] - The total assets increased to ¥9,699,462,636.70 from ¥9,341,677,723.81, showing a growth of approximately 3.8%[24] - The total liabilities increased to ¥3,779,901,199.51 from ¥3,675,567,489.25, reflecting a growth of about 2.8%[24] - The total owner's equity rose to ¥5,919,561,437.19 from ¥5,666,110,234.56, indicating an increase of approximately 4.5%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,537[12] - The largest shareholder, Ningbo Kaiming Investment Management Partnership, holds 19.03% of shares, equating to 80,064,000 shares[12] - Zhejiang Jihe Venture Capital holds 12.91% of shares, totaling 54,324,000 shares[12] - The top 10 shareholders collectively hold significant stakes, with the top four shareholders accounting for 41.14% of total shares[12] - The actual controller, Ding Li Ming, indirectly controls 21.39% of shares through partnerships[12] - The company has no changes in the top 10 shareholders due to securities lending or borrowing compared to the previous period[13] - There are no preferred shareholders or changes in restricted shares reported for this period[13] - The company has a total of 0 preferred shareholders at the end of the reporting period[13] - The total number of shares held by the top 10 unrestricted shareholders is 80,064,000 shares[12] - The company has not disclosed any related party transactions among shareholders outside of the top shareholders[12] Operational Highlights - The company reported a significant increase in accounts receivable by 229.24% to ¥324,186,069.06, attributed to increased sales and outstanding receivables[10] - The company launched eight products, including the recently approved drugs Enasatinib and Tarecitinib, contributing to revenue growth[15] - The company has strategic partnerships, including a collaboration with Hangzhou Bozhirui Biopharmaceutical Co., which commenced nationwide sales of a new product in July 2025[16] - The company is advancing clinical trials for several drugs, including MCLA-129, which has completed patient enrollment for a Phase II study in lung cancer[17] - The company reported a 2-year disease-free survival rate of 86.4% for Enasatinib in postoperative adjuvant therapy, significantly reducing the risk of disease recurrence[17] Cash Flow and Investments - Operating cash inflow for the current period was CNY 2,737,853,928.25, an increase of 7.43% from CNY 2,548,182,394.10 in the previous period[28] - Net cash flow from operating activities decreased to CNY 668,430,246.92, down 19.6% from CNY 831,340,738.79 in the previous period[28] - Cash outflow from investing activities totaled CNY 731,485,187.19, compared to CNY 783,733,321.62 in the previous period, indicating a decrease of 6.67%[28] - Net cash flow from financing activities was CNY 2,786,569.40, a significant improvement from a net outflow of CNY 200,294,076.80 in the previous period[29] - The total cash and cash equivalents at the end of the period decreased to CNY 414,329,858.11 from CNY 595,341,383.28, reflecting a decline of 30.4%[29] - Cash inflow from financing activities increased to CNY 809,946,278.00, up from CNY 483,600,000.00 in the previous period, representing a growth of 67.5%[29] - Cash outflow for purchasing goods and services rose to CNY 402,612,013.17, compared to CNY 207,021,761.38 in the previous period, marking an increase of 94.5%[28] - The company reported a cash inflow of CNY 90,716,752.84 from other operating activities, up from CNY 75,478,085.66, an increase of 19.5%[28] - The company’s cash flow from investment activities showed a net outflow of CNY 730,471,677.77, slightly improved from CNY 781,682,505.65 in the previous period[28] - The impact of exchange rate changes on cash and cash equivalents was a positive CNY 1,901,864.44, compared to a negative impact of CNY 6,019,687.56 in the previous period[29] Research and Development - The company reported a decrease in research and development expenses to ¥372,969,710.80 from ¥384,037,587.90, a decline of approximately 2.9%[26] - Long-term equity investments rose to ¥599,381,502.98 from ¥360,541,773.33, an increase of about 66.3%[23]